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Abstract 
Background 
Population-based cancer survival is one of the important measures of the overall effectiveness 
of cancer care in a population. Population-based cancer registries collect data that enable the 
estimation of cancer survival. To ensure accurate, consistent and comparable survival 
estimates, strict control of data quality is required before the survival analyses are carried out. 
In this paper, we present a basis for data quality control for cancer survival.  
Methods 
We propose three distinct phases for the quality control. Firstly, each individual variable 
within a given record is examined to identify departures from the study protocol; secondly, 
each record is checked and excluded if it is ineligible or logically incoherent for analysis; 
lastly, the distributions of key characteristics in the whole dataset are examined for their 
plausibility.  
Results 
Data for patients diagnosed with bladder cancer in England between 1991 and 2010 are used 
as an example to aid the interpretation of the differences in data quality. The effect of 
different aspects of data quality on survival estimates is discussed.  
Conclusions 
We recommend that the results of data quality procedures should be reported together with 
the findings from survival analysis, to facilitate their interpretation. 
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1 Introduction 
 
Population-based cancer survival is one of the important measures of the overall effectiveness 
of cancer care and control in a population, alongside incidence and mortality. Trends in 
cancer survival provide further indication of improvements in diagnosis and treatment.1  
 
Standard checks required for cancer incidence data have been described2-4 and are embodied 
in the widely used IARC Check program.5 However, additional quality checks are required 
for survival analysis, as the completeness and validity of data on vital status (alive, dead or 
lost to follow up) and follow-up time of the patients become crucial.  
 
The interpretation of survival comparisons between countries or populations (defined by 
calendar period, socio-economic status, race or ethnicity) relies on the thoroughness of 
quality control procedures, which ensure that incomplete, ineligible or incoherent tumour 
records are flagged and excluded. We describe a set of quality control procedures that have 
been applied to population-based data for several recent national and international studies of 
cancer survival.6-9 This set of procedures can form a basis for data quality control in cancer 
survival analysis.  
 
2 Materials and Methods 
 
2.1 Cancer registry data 
 
Cancer registries collate data from sources such as hospitals, general practitioners, pathology 
departments, cancer referral units and screening programmes, and obtain one record for each 
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tumours including patient demographic (date of birth, sex, residence or postcode, ethnicity, 
patient identifier), tumour (date of diagnosis, topography, morphology, behaviour, 
microscopic confirmation, stage at diagnosis), treatment (surgical procedure, chemotherapy, 
radiotherapy) and outcome (date and place of death) data. 10,11 This process may not be 
completed for six to nine months, until a patient’s course of treatment has finished. 
 
Information on the patient’s vital status is later added from sources such as the regional or 
national death indexes, social security, health insurance, death certificates, physician or 
hospital contacts and/or home visits. The key concern is that the eventual deaths of all 
registered cancer patients are recorded. The quality and completeness of this information is 
essential for accurate estimation of survival. 
 
2.2 Defining the cancers  
 
Cancers are defined by their anatomic location (site) and microscopic appearance 
(morphology), and whether they are benign, in situ, malignant or of uncertain behaviour 
(behaviour), under the International Classification of Diseases12 or the International 
Classification of Disease for Oncology.13 Various utilities exist to convert ICD codes 
between the various revisions.14,15  
 
In what follows, we write from the perspective of a general cancer registry, with data on all 
cancers.  
 
2.3 Quality control 
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Quality control procedures are designed to ensure that survival analyses include only patients 
resident in the defined territory who were diagnosed with a primary, invasive, malignant 
neoplasm during a defined calendar period, and whose tumour record is valid and logically 
coherent.16 
 
We propose three distinct phases for the quality control of cancer data for survival analysis 
(Figure 1). In the following sections, we will describe the rationale and process for each of 
these phases with accompanying examples. As any data quality control process, feedback is 
provided to the data sources, i.e. the registries, which will result to data checks and may lead 
to modifications. In a study involving several registries, quality control would entail 
discussion between the analytic centre and the registry concerned. 
 
Phase 1: Protocol adherence (variables) 
 
Are the individual variables within a given record compliant with protocol? A protocol 
specifies all permissible values for each variable,9 such as last known vital status: alive=1, 
dead=2, lost to follow-up=3, unknown=9 (Table 1), or that the month of a date is in the range 
1-12. Protocol adherence involves checking each variable in each record to confirm that its 
value falls within the specified range, and tabulating the number and proportion of variables 
that meet the protocol definitions (Table 2). Records containing variables that are not 
compliant with protocol should be reviewed for correction or re-coding. Data sets with 
substantial proportions of error will require further detailed checks by the cancer registry 
concerned.  
 
Phase 2: Eligibility and exclusion (records) 
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Are the variables in each record eligible and logically coherent for analysis? We recommend 
a two-stage selection process (Table 3). 
 
Tumour records in the raw data are first selected as eligible for analysis only if they are for an 
invasive, primary, malignant neoplasm diagnosed during the period defined for analysis in a 
patient who was resident in the territory covered by the registry. In situ, non-malignant or 
secondary tumours should be excluded. 
 
Next, each eligible tumour record is checked for internal logical coherence and validity for 
inclusion in survival analyses. Such checks include that the day, month and year of each date 
are coherent, the sequence of dates is plausible (e.g. diagnosis precedes or is equal to the date 
of death), that the vital status and sex are both known, and that the cancer was not registered 
only from a death certificate (death-certificate-only, or DCO) or from an autopsy. Duplicate 
registrations, synchronous tumours and second (third, etc.) primary cancers (often referred to 
as multiple primary tumours) at the same anatomic site are also excluded. However, we 
recommend retention in the analyses of eligible multiple primary tumours which are not at 
the same anatomic site as an earlier tumour.17,18  
 
From a practical perspective, automated programs embodying the criteria mentioned above 
are applied. Each tumour record is checked against both the ineligibility and exclusion 
criteria, and assigned one or more error flags, as applicable.  All records that fail one or more 
criteria are then excluded from the data in a defined sequence of descending severity, 
applying the most basic reasons for exclusion first. Counts are made of the number of tumour 
records that fail each criterion, and a separate count is made of the number and proportion of 
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patients excluded from the data on the basis of each criterion. The results can be presented in 
standard tables to facilitate examination of data quality. The tables show the total number of 
records in the raw data, the number that remain after removal of ineligible records, the 
number (and proportion of eligible patients) excluded because the tumour record failed one or 
more criteria, and finally the number of patients whose data can be included in survival 
analysis. The results of this process would lead to review and revision of the data if errors are 
confirmed. An example is shown in Table 4, based on the data preparation for a recent 
analysis to produce the official National Statistics for cancer survival in England.19 
 
It is particularly important to check the dates and their sequence in each tumour record. 
Complete dates (day, month, year) should be used in survival analysis, because estimates of 
survival are otherwise biased, particularly for short-term survival.20 Individual dates should 
be checked for validity (e.g. 31 February is invalid). The sequence of the dates of birth, 
diagnosis and last known vital status must also be logically coherent (see Table 3). Records 
with the date of diagnosis outside the predefined range should be excluded. Similarly, records 
with the date of last known vital status after the predefined end of follow-up (and before the 
date of data extraction) should be censored as alive at the date of end of follow-up. The 
distribution of the day and month of each date should also be examined. For example, peaks 
of distribution of certain values (e.g. 15 for days) reflect high proportion of imputed dates.   
 
Phase 3: Distribution of key characteristics – editorial tables (data sets) 
 
Editorial tables are used to examine aspects of data quality in the data file as a whole. For 
example, one should examine the number and proportion of DCO registrations over time and 
the distribution of cancers by deprivation or ethnicity over time. These tables are useful in 
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examining the data for a single registry, but also in comparing the data sets for many 
registries (Table 5). 
 
The basic distributions of the key variables in the records are analysed, such as the counts of 
cases by year of diagnosis, distribution of DCOs by age or time, or the proportion of tumours 
with morphological verification and the actual distribution of morphology. Editorial tables 
permit greater visual scrutiny of the data, such as differences in the proportion of DCO by 
age, time or socio-economic status. This enables comparisons between different deprivation 
categories, years and cancer registries.  
 
Exclusion and editorial tables are shared with the registry, both to help identify improbable 
distributions of variables, and to document trends in data quality over time. For studies with 
more than one cancer registry, such tables provide valuable comparative information. 
 
 
3 Results 
 
Data quality control processes help to shed light on observed survival differences between 
geographical regions and over time periods. Differences in the proportion of tumour records 
that were eligible for survival analyses could reflect differences in data quality or in 
diagnostic and coding practices.  
 
3.1 Interpretation of differences in data quality  
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An English dataset including bladder cancer patients diagnosed between 1991 and 2010 is 
used as an example. Recommendations to exclude some papillary tumours of the bladder that 
would previously have been classified as invasive were implemented by UK cancer registries, 
for tumours registered from 2000.21,22 Patients with urothelial papillary tumours with high 
survival who would have been included in survival analyses prior to 2000 may then have 
been excluded for analyses if diagnosed after 2000.  
 
This change would not be reflected at the protocol adherence phase, as there is no change in 
the range of morphology codes for bladder cancer. However, the change in coding practice 
can be faithfully represented in the exclusion table (Table 4).; the proportion of registered 
patients with benign or uncertain tumours of the bladder increased dramatically from 2.8% 
for patients diagnosed in 1991-1995 to 29.3% in 2006-2010, which leads to an increase in the 
proportion of ineligible patients from 10.6% to 45.1%.  
 
This was also clear in the tabulation of new cases by morphology and year of diagnosis in 
editorial tables. A drastic drop in number of patients diagnosed with invasive bladder cancer 
with morphology codes 8120 and 8130 in the year 2000 was observed, as the result of the 
change in the coding practice (Figure 2). 
 
This change would produce an artificial downward trend in bladder cancer survival, without 
any real change in survival times for patients with genuinely invasive malignancy. It would 
produce a downward trend in bladder cancer incidence, but would not influence observed 
mortality. Regional variations in survival and incidence within England may also be 
explained by this change in practice; the change in coding practice happened gradually in the 
different regional cancer registries between 1986 and 1999.23 Data quality control processes 
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can thus highlight potential artefacts in the data that can inform the interpretation of survival 
estimates.   
 
Potential differences and changes in the quality of cancer registration can also be evaluated. 
For bladder cancer in England, the number of DCO registrations decreased from 4.3% in 
1991 to 1.8% in 2010 (Table 4), which reflects an improvement in the quality of cancer 
registration in England. Similarly, data quality difference between registries can be assessed 
by the completeness and validity of vital statistics information and by the proportion of 
records with DCOs.   
 
Other factors can also influence the comparability and continuity of registration data for 
survival analyses. For example, introduction of screening programmes (e.g. for breast cancer) 
allows the detection of a high proportion of low stage cancers, which would result in an 
increase in cancer survival estimates. The exclusion and editorial output from the data quality 
control process would offer an insight to these changes. Survival trends should also be 
interpreted alongside trends in incidence and mortality.  
 
4 Discussion  
 
This paper provides an overview of the data quality control methods currently used by the 
Cancer Research UK Cancer Survival Group to prepare population-based cancer registry data 
for the estimation of cancer survival. We recommend application of strict data quality control 
procedures to ensure internally valid and externally comparable survival estimates. This 
monitoring of quality control methods is a continuous process.5 It involves routine checking 
for validity and consistency, and maintenance and updating of the cleaning programmes that 
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are used to identify and flag inconsistencies or possible errors, and to present the results in 
suitable tables and graphics.  
 
It is impossible to be completely prescriptive about all the quality-control tests that should be 
conducted before analysis of survival in a given data set. For example, if the analyses will 
involve examination of survival by stage at diagnosis, it will be necessary to perform tests of 
the completeness and validity of the data on stage, and perhaps to perform multiple 
imputation for missing values of stage. The range of tests to be performed will also depend 
on the variables that are collected by the cancer registry concerned; and in the case of a 
comparative analysis involving several registries, on the variables included in the study 
protocol. 
 
However, several key variables required for population-based survival analyses must be 
completely and accurately recorded in the registry for accurate estimation of survival. For 
example, if follow-up for patient’s vital status is not complete and deaths are not all recorded 
properly (error in the ‘vital status’ variable), patients may become ‘immortals’ (Table 5) and 
over-estimation of survival would occur. In this case, a cleaning process which allows the 
identification of probable ‘immortals’ would be essential for estimating the scale of the 
problem. Ideally, full dates of birth, dates of diagnosis and dates of follow-up should always 
be used to ensure complete data assessment and unbiased survival estimation.20  
 
By contrast, we recommend inclusion in survival analyses of patients who died on the same 
day as the diagnosis of their cancer. It may be necessary to assume for these patients that 
death occurred one day after diagnosis, if the statistical software cannot deal with zero 
survival time. Excluding such observations would artificially over-estimate survival. 
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Cancer registrations based solely on a death certificate (death-certificate-only or DCO 
registrations) are assigned to the date of death for the purposes of cancer incidence, but they 
cannot be included in survival analyses24 because the duration of survival is unknown. If 
DCOs represent a high proportion of all registered cases, this suggests under ascertainment of 
incident cases. If the true (but unknown) duration of survival for patients registered as a DCO 
is shorter than the average, a high proportion of DCO cases may also lead to over-estimation 
of survival.25  The proportion of DCOs will be zero in countries where death certificates are 
not used to initiate a new cancer registration or where access to the cause of death is not 
legal; this may give rise to some under registration of incident cases. 
 
The choice of whether to include the second, third (etc.) tumour in a given person (multiple 
primary) in survival analyses will affect the interpretation of results. We recommend 
excluding multiple primaries at the same anatomic site. Including multiple primaries at the 
same site would permit inclusion of two deaths for a single person in the same survival 
analysis of a type of malignancy (typically define by ICD-O topography codes). Multiples 
with different morphology within the same organ remain rare. It is statistically feasible to 
allow the same person to contribute two events (e.g. episodes of influenza) in a cohort 
analysis of endpoints. However, in practice, because morphology remains missing or is too 
general in high proportions in many registries, it seems safer to exclude all multiples at the 
same site for the ease of comparison between registries and over time. 
 
By contrast, it is generally advisable to include a person with two malignancies that have 
occurred at different anatomic sites in the analysis of survival for each of the sites. Including 
multiple primaries at different sites reduces the bias in comparison of survival between 
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registries due to different observation periods, age, registration quality and completeness of 
registration.18 For example, if we were to exclude them, a subsequent cancer of a patient 
would be excluded in a registry with records of the first cancer, while it would be treated as 
the first cancer in a younger registry and included in survival analyses; this would bias 
survival comparisons. Including multiple primary tumours also avoids the conceptual 
difficulties that arise from the definition of multiple primary malignancy, which differs 
widely between the two main sets of international rules (SEER and IARC).26,27 The general 
effect of inclusion is to reduce survival estimates by a variable amount depending on the 
proportion of multiple primaries, the cancer site, and the extent to which survival for 
subsequent tumours is shorter than for first primary tumours.17 One final caveat, which is that 
if we are to analyse survival from all cancers combined, in which we pool the data from more 
than one anatomic site as typically defined, then it would again become inappropriate to 
include a single person more than once in the analyses, which should then be confined to first 
primary malignancies. 
 
We recommend consistent application of data quality checks in preparing population-based 
data for the estimation of cancer survival, in order to ensure accuracy, consistency and 
comparability of the estimates. The data quality assurance procedures should be reported 
when presenting the results of survival analyses, in order to facilitate their interpretation. 
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Table 1 
 
 
  
Short description Type
a
No. of digits
 or characters
Valid values
(or range of valid 
values)
Value to be used
when valid data
are missing
Unique ID
b
A Not allowed
Sex N 1 1,2 9
Day of birth N 1 or 2 1-31 99
Month of birth N 1 or 2 1-12 99
Year of birth
c
N 4 1895-2010 9999
Day of diagnosis N 1 or 2 1-31 99
Month of diagnosis N 1 or 2 1-12 99
Year of diagnosis
c
N 4 1995-2010 9999
Last known vital status
d
N 1 1,2,3 9
Day of last known vital status N 1 or 2 1-31 99
Month of last known vital status N 1 or 2 1-12 99
Year of last known vital status
c
N 4 1995-2010 9999
ICD-O-3
e
 Topography A 4 C00.0-C80.9 Not allowed
ICD-O-3
e
 Morphology N 4 8000-9989 9999
Behaviour
f
N 1 0,1,2,3,6,9 Not allowed
a
 A - Alphanumeric; N - Numeric
b
 Recognised only within the cancer registry (to enable correction of errors).
d
 Last known vital status: 1 - alive, 2 - dead, 3 - lost to follow-up, 9 - unknown 
Depending on the source cancer registry
f
Behaviour of neoplasm: 0 - Benign; 1 - Uncertain whether benign or malignant; 2 - Malignant carcinoma in situ; 3 - Malignant,
primary site; 6 - Malignant, metastatic site; 9 - Malignant, uncertain whether primary or metastatic site
e
Anatomic site and morphological type of neoplasm, coded to: World Health Organisation. International Classification of
Diseases for Oncology (ICD-O). In: Fritz AG, Percy C, Jack A, Shanmugaratnam K, Sobin LH, Parkin DM, Whelan SL, eds., 3rd 
ed. Geneva: World Health Organisation, 2000.
c
The valid values for these variables depends on the eligible years of diagnosis, years of follow-up and age of patient in a
predefined study protocol. Here, the date of diagnosis and follow-up are defined to be between 1st of January 1995 and 31st
December 2010 and that patients under 100 years of age are eligible for the study.  
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Table 2 
 
  
Variable name Short description Coding allowed No. % No. % No. %
VAR1 Unique ID Up to 15 alphanumeric 383,895 100 251,274 100 341,769 100
VAR2 Sex 1-digit = 1, 2, 9 383,895 100 251,274 100 341,769 100
VAR3 Day of birth 1-2 digit 1-31, 99 383,887 >99 251,269 >99 341,659 >99
VAR4 Month of birth 1-2 digit 1-12, 99 383,887 >99 251,269 >99 341,659 >99
VAR5 Year of birth 4-digit 383,887 >99 251,274 100 341,769 100
Compliant
Colorectal Lung
Compliant
Breast
Compliant
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Table 3 
Definition Comment 
Ineligible records 
Incomplete data Incomplete data item(s) such as sex, date of birth, date of diagnosis 
(for non-death-certificate-only records), date of last known vital 
status, postcode, site, morphology, and behaviour 28 
Not belonging to the population of 
interest  
Checked when the postcode information is added 
In situ neoplasm Behaviour code 2 
Benign, or uncertain if benign or 
malignant 
Behaviour code 0 or 1 
Metastatic Behaviour code 6 or 9 
Otherwise ineligible Tumour specific checks on ICD codes such as anatomic location, 
morphology or behaviour, specific to a particular malignancy  
Lymphoma a in a solid organ Morphology for lymphoma in a solid organ 
Leukaemia a or myeloma in a solid 
organ 
Leukaemia or myeloma in a solid organ  
Exclusion criteria 
Aged 100+ If cases are aged 100 years or more at diagnosis  
Vital status unknown   If vital status is not known by the ‘freeze date’ b  
Sex not known Sex code 9 
Sex-site incompatibility  Sex-specific tumours not compatible with recorded sex  
Invalid dates or invalid sequence of 
dates  
Dates of birth, diagnosis, death or censoring  do not correspond to a 
real date; or sequence of dates is impossible  
Death certificate only (DCO)   Case identified only by death certificate or case identifies only by 
autopsy 
Duplicate registration  Identified if records have the same site code, sex, personal 
identification number (or cancer registry number), and cancer registry 
as another registration  
Synchronous tumours  Synchronous tumours at a single site are considered one cancer24. 
Further synchronous records can be identified and excluded if two 
records are associated with the same site code, sex, date of birth, date 
of diagnosis and/or other combinations of identifiable information 
Multiple primary at the same site  Multiples may be identified if two records have the same personal 
identification number and are of the same site, but with different 
dates of diagnosis 
a ICD-O-3 morphology: 9590-9999 
b The freeze date of a database is the date after which the database no longer updates with new information.  
  
21 
 
Table 4 
 
Total registered 62,331 100.0 67,993 100.0 72,517 100.0 80,165 100.0
Ineligible Patients % Patients % Patients % Patients %
Incomplete data 130 0.2 75 0.1 101 0.1 10 <0.1
Not resident in England 96 0.2 70 0.1 5 <0.1 2 <0.1
In situ neoplasm 4,573 7.3 11,006 16.2 11,255 15.5 12,621 15.7
Benign or uncertain 1,760 2.8 5,013 7.4 17,895 24.7 23,460 29.3
Metastatic 49 <0.1 31 <0.1 53 <0.1 65 <0.1
Otherwise ineligible
a
11 <0.1 8 <0.1 0 0.0 0 0.0
Lymphoma
b
0 0.0 0 0.0 0 0.0 0 0.0
Leukaemia or myeloma 0 0.0 0 0.0 0 0.0 0 0.0
Total ineligible
c
6,619 10.6 16,203 23.8 29,309 40.4 36,158 45.1
Total eligible 55,712 100.0 51,790 100.0 43,208 100.0 44,007 100.0
Aged 100+ 23 <0.1 28 <0.1 28 <0.1 41 <0.1
Vital status unknown 222 0.4 128 0.2 81 0.2 87 0.2
Sex not known 0 0.0 0 0.0 0 0.0 0 0.0
Sex-site error 0 0.0 0 0.0 0 0.0 0 0.0
Invalid dates 16 <0.1 2 <0.1 9 <0.1 1 <0.1
Death certificate only 2,387 4.3 1,688 3.3 1,064 2.5 790 1.8
Duplicate registration 0 0.0 0 0.0 0 0.0 0 0.0
Synchronous tumours 166 0.3 262 0.5 68 0.2 59 0.1
Multiple primary same site 80 0.1 90 0.2 94 0.2 128 0.3
Total exclusions
d
2,894 5.2 2,198 4.2 1,344 3.1 1,106 2.5
Patients available for analyses 52,818 94.8 49,592 95.8 41,864 96.9 42,901 97.5
a Other criteria of anatomic location, morphology or behaviour, specific to a particular malignancy. In general, they 
refer to secondary malignancy at relevant site. 
b Morphology for lymphoma in a solid organ excluded for survival analysis at the solid organ site. These cases of 
lymphomas would be included in the lymphoma analysis. 
c Of total registered patients.
d Of total eligible patients.
1991-95 1996-2000 2001-05 2006-2010
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Table 5  
Type1 Data quality 
 1) The distribution of the day and month (and year) of the date of birth, date of diagnosis and 
date of death (or lost to follow-up), which should be, at least for day and month, roughly 
uniform 
2) No. (%) of records representing multiple primaries at different sites by calendar year 
 3) No. (%) of Death Certificate Only (DCO) registrations by cancer and year of registration 
 4) No. (%) of records with morphological verification, by cancer and year of diagnosis 
 5) No. (%) of records with implausible age or duration of survival by cancer and year of 
diagnosisa  
Type 2 Descriptive counts and proportion: (No./%) 
 6) Cancer by sex and year of diagnosis  
 7) Cancer, deprivation and/or ethnicity and year of diagnosis 
 8) Morphology groupb by cancer, year and period of diagnosis  
a Referred to as ‘immortals’. Depending on the study design, ‘immortals’ may be defined as patients aged 105 
years or over who are not known to have died, or who have apparently survived five or more years from a 
highly lethal cancer, e.g. brain, oesophagus, stomach or pancreas. They should be defined prior to the analysis, 
and may be systematically excluded from the data. 
b Berg et al 1996 
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